In this video health care analysts David Williamson and Max Macaluso discuss Pfizer's just-released third-quarter earnings. David distills the highlights and hits on all of the critical takeaways for investors, including potential blockbuster Eliquis shared with Bristol-Myers Squibb and the "bapi" Alzheimer's failure, which it shares with Elan. Watch and discover everything you need to know about Pfizer's most recent quarter.
Pfizer Earnings: Critical Takeaways
By Dave Williamson – Nov 1, 2012 at 5:18PM
NYSE: PFE
Pfizer
Market Cap
$141B
Today's Change
(0.97%) $0.24
Current Price
$24.85
Price as of November 6, 2025 at 4:00 PM ET
Everything you need to know in 1 short video.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid